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Epstein-Barr virus is known to cause nasopharyngeal carcinoma. Although oral cavity is located close to the nasal pharynx, the
pathogenetic role of Epstein-Barr virus (EBV) in oral cancers is unclear. This molecular epidemiology study uses EBV genomic
microarray (EBV-chip) to simultaneously detect the prevalent rate and viral gene expression patterns in 57 oral squamous cell
carcinoma biopsies (OSCC) collected from patients in Taiwan. The majority of the specimens (82.5%) were EBV-positive that
probably expressed coincidently the genes for EBNAs, LMP2A and 2B, and certain structural proteins. Importantly, the genes
fabricated at the spots 61 (BBRF1, BBRF2, and BBRF3) and 68 (BDLF4 and BDRF1) on EBV-chip were actively expressed in a
signiﬁcantly greater number of OSCC exhibiting exophytic morphology or ulceration than those tissues with deep invasive lesions
(P = .0265 and .0141, resp.). The results may thus provide the lead information for understanding the role of EBV in oral cancer
pathogenesis.
Copyright © 2009 Ching-Yu Yen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Most oral cancer is squamous cell carcinoma that originates
from outgrowth of the mucosal epithelium. Ulcerative and
irregular surfaces at the border of cancerous tissues are
the most common morphologic manifestations. Not only
is the tumor resistant to therapeutic treatments but also it
is accompanied frequently with serious pain, especially in
patients at late stages [1]. In recent years, the prevalence rate
for oral cancer in Taiwan has dramatically increased. The
statistical data published in 2004 Taiwanese Health and Vital
Statistics (Department of Health or DOH, Taiwan, ROC)
showed that the oral cancer incidence rate in Taiwan is 1.5
to more than 4-folds higher than that in Germany, Japan,
Korea,Singapore,theUK,ortheUSA.Infact,theoralcancer
incidence rate among Taiwanese males steadily increased
over the years and reached 22.7 and 25.3 per 100000 in
1998 and 1999, respectively. These ﬁgures are at least double
of those found in USA (1975–2003 SEER Cancer Statistics
Review, National Cancer Institute, USA) and markedly
higher than those in some European (Spain and France) and
Asian (Cambodia and Bangladesh) countries, as revealed in
a survey conducted by the International Agency for Research
on Cancer (IARC) in 2002. Unsurprisingly, according to
Cancer Registry Report, 2005 published (on April 11, 2008)
by Bureau of Health Promotion, DOH in Taiwan, oral cancer
was the number one cancer among males of 25 to 44 years
old. Therefore, the control of oral cancer and improving2 Journal of Biomedicine and Biotechnology
the outcomes of treatments have become urgent issues for
Taiwan.
Many factors, including the habit of betel quid chewing
[2] and viral infections, have been investigated for their
association with the tumorigenesis of oral cancer, in the
hope to gain a better understanding of the biology of the
cancer and possibly develop eﬀective means to increase
the overall survival rate. Although the oral cavity, which
contains a large area of the epithelium, is located close
to the nasal pharynx, the association of oral cancer with
Epstein-Barr virus (EBV) is uncertain, but infection by
the virus has been linked to nasopharyngeal carcinoma
(NPC) [3, 4]. EBV, a γ-herpesvirus, is ubiquitously present
in the human population. Infection by EBV is known to
cause infectious mononucleosis and is associated with many
human lymphoid and epithelial cancers, including Burkitt’s
lymphoma, gastric cancer, T cell lymphoma, Hodgkin’s
disease, and NPC [3, 5]. Many studies have shown that
the expression of viral latent genes, especially genes for
EBNAs(EBV-associatednuclearantigens)andLMP-1(latent
membrane protein-1), has been closely associated with
latent infection that correlates with immortalization and
tumorigenesis. In recent years, more evidences show that
EBV is found in tumors of bladder [6], breast [7], cervix
[8], gastric [9] or gastrointestinal tract [10], kidney [11],
lung [12], skin [13], and thyroid [14]. Unfortunately, the
role of the virus in the formation of these cancers remains
uncertain. Owing to the increase in EBV detection in
many cancers, numerous molecular surveys on oral cancer,
which used mainly polymerase chain reaction (PCR) and
in situ hybridization methods to detect viral DNA and
RNA transcripts, have been performed in many geographic
areas worldwide, including Asian and European countries.
Among those investigations reporting the detection of EBV
in oral squamous cell carcinomas (OSCCs) in the past
decade, the viral prevalent rates varied greatly, ranging
from 15% to 77% [15–24], whereas few studies showed
the total absence of EBV in the OSCC specimens [25, 26].
These discrepancies in viral prevalent rates may have been
attributed to the methods of cancer biopsy preparation
and preservation, the selections of gene targets, and/or the
techniques of detections. In EBV-positive OSCC, only a
limited number of viral genes have been screened for their
expressions; EBER and EBNA2 transcripts were analyzed
by in situ hybridization [17, 20, 22, 26, 27]a n dE B N A 1 ,
EBNA2, LMP-1, ZEBRA, and Zta proteins were stained
by immunological methods [17, 20, 22, 27]. Although
great eﬀorts had been made in these studies, the etiologic
and tumorigenic roles of the virus in oral cancer remain
unclear.
The recent advance in microarray technology allows
scientists to fast and simultaneously detect diﬀerent viral
genomic sequences or globally proﬁle the viral gene expres-
sion patterns with a great speciﬁcity and sensitivity; the most
substantial and feasible case has been the demonstration of
developing and analyzing the opportunistic viral infections
in AIDS pathogenesis with a multivirus array containing
eight human viruses [28]. In order to determine accurately
the prevalent rate for the potential viral etiologic agent in
OSCC, newly developed EBV genomic microarray (EBV-
chip) [29, 30] is used in the current study. EBV-chip, which
contains viral DNA spots covering the entire EBV genome,
is hybridized with biotin-labeled cDNA derived from OSCC
biopsies for detecting the presence of viral transcripts.
This determines simultaneously the viral infection rate
and the gene expression patterns in the cancer tissues
studied. The hybridization method has not only similar
sensitivity as PCR [31] but also the advantage of preventing
false PCR identiﬁcation due to carry-over contaminations.
Furthermore, since the viral genomic microarray can detect
multiple gene transcripts simultaneously, which cannot be
achieved by other hybridization methods, the reliability of
positive identiﬁcation of EBV present in tumor cells is
greatly increased. This study ﬁnds that 47 out of 57 OSCC
specimens were EBV-positive that expressed coincidently the
genes for EBNAs, LMP2A and 2B, and certain structural
proteins. Importantly, the genes fabricated at the spots 61
and 68 on EBV-chip were actively expressed in a signiﬁcantly
greater number of OSCC exhibiting exophytic morphology
or ulceration than those tissues with deep invasive lesions.
The results of EBV-chip hybridization may thus provide the
lead information for understanding the role of EBV in oral
cancer pathogenesis.
2.MaterialsandMethods
2.1. Patients and Cell Lines. OSCC tissue specimens were
collected from patients who were admitted to the hospital
and underwent surgical procedures between 1999 and 2002
under patients’ consent. After surgery, all patients were
subjected to follow-ups for at least four years to evaluate
their prognostic progresses. The general characteristics and
clinical ﬁndings of the patients are listed and summarized
in Tables 1 and 2, respectively. Cell lines used in this
study included B95-8, which was EBV-infected marmoset
blood leukocytes with continuous viral replication, and
P3HR1, which was derived from Burkitt’s lymphoma and
was latently infected by EBV. B95-8 and P3HR1 cells
were cultured in RPMI 1640 medium (GIBCO, Invitrogen,
Grand Island, NY, USA) supplemented with 10% bovine
calf serum (HyClone, Logan UT, USA) and 1% Penicillin-
Streptomycin (GIBCO). The EBV lytic cycle in P3HR1 cells
was induced with 3ng/mL of 12-O-tetradecanoylphorbol-
13-acetate (TPA; GIBCO) and 3mM sodium butyrate (SB;
Sigma-Aldrich, St. Louise, MO, USA). Enzymes used in this
study were purchased from Stratagen (La Jolla, CA, USA)
unless otherwise speciﬁed; common chemicals and reagents
were from Sigma-Aldrich.
2.2. Microarray Analysis and Real-Time RT-PCR Conﬁr-
mation. EBV-chip was produced according to a method
described elsewhere [29] .T h i sv i r a lg e n o m em i c r o a r r a y
was fabricated with 71 consecutive PCR-ampliﬁed EBV
DNA fragments of 1–3kbp covering the entire 172-kbp
viral genome and 12 control gene fragments, including the
genes for human β-actin and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) [29, 30]. The organization ofJournal of Biomedicine and Biotechnology 3
Table 1: Characteristics of patient subjects participated in EBV-chip detection.
Number(a) Gender Age Number of lesion(b) Site(c) Type of the primary SCC
1M a l e 5 01 P a l a t e U l c e r a t i v e
2M a l e 4 73
Primary: Buccal mucosa, SCC
Exophytic Secondary: Buccal mucosa, Leukoplakia
Tertiary: Palate, VH
3 Male 47 1 Gingiva Exophytic
4M a l e 4 61 P a l a t e E x o p h y t i c
5M a l e 4 83
Primary: Buccal mucosa, SCC
Exophytic Secondary: Buccal mucosa, SCC
Tertiary: Buccal mucosa, VH
6 Male 79 1 Buccal mucosa Ulcerative
7M a l e 5 13
Primary: Tongue, SCC
Ulcerative Secondary: Tongue, SCC
Tertiary: Buccal mucosa, SCC
8M a l e 4 94
Primary: Palate, SCC
Exophytic
Secondary: Palate, SCC
Tertiary: Buccal mucosa, VH
Quaternary: Lip, VH
9 Male 47 1 Retromolar trigone Ulcerative
10 Male 53 1 Gingiva Ulcerative
11 Male 47 3
Primary: Buccal mucosa, SCC
Exophytic Secondary: Buccal mucosa, SCC
Tertiary: Gingiva, Leukoplakia
12 Male 50 1 Buccal mucosa Exophytic
13 Male 53 1 Buccal mucosa Exophytic
14 Male 47 1 Gingiva Ulcerative
15 Male 45 1 Gingiva Ulcerative
16 Male 44 1 Tongue Ulcerative
17 Male 47 4
Primary: Buccal mucosa, SCC
Exophytic Secondary: Buccal mucosa, SCC
Tertiary: Retromolar trigone, SH
Quaternary: Lip, SH
18 Male 56 1 Buccal mucosa Exophytic
19 Male 36 1 Gingiva Ulcerative
20 Male 49 2 Primary: Buccal mucosa, SCC Ulcerative
Secondary: Tongue, VH
21 Male 46 1 Tongue Deep invasive
22 Male 43 3
Primary: Gingiva, SCC
Ulcerative Secondary: Buccal mucosa, SCC
Tertiary: Gingiva, VH
23 Male 53 1 Tongue Ulcerative
24 Male 52 4
Primary: Buccal mucosa, SCC
Exophytic Secondary: Buccal mucosa, SCC
Tertiary: Palate, VH
Quaternary: Lip, VH
25 Male 65 4
Primary: Gingiva, SCC
Exophytic Secondary: Gingiva, SCC
Tertiary: Gingiva, VH
Quaternary: Oropharynx, VH
26 Male 59 1 Gingiva Ulcerative
27 Male 41 1 Buccal mucosa Exophytic
28 Male 54 1 Tongue Exophytic
29 Male 75 1 Gingiva Ulcerative
30 Male 32 1 Buccal mucosa Exophytic4 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Number(a) Gender Age Number of lesion(b) Site(c) Type of the primary SCC
31 Male 33 2 Primary: Buccal mucosa, SCC Deep invasive
Secondary: Buccal mucosa, VH
32 Male 48 1 Tongue Exophytic
33 Male 54 4
Primary: Buccal mucosa, SCC
Exophytic
Secondary: Buccal mucosa, SCC
Tertiary: Buccal mucosa, SCC
Quaternary: Lip, SCC
34 Male 47 1 Buccal mucosa Exophytic
35 Male 40 1 Palate Ulcerative
36 Male 34 1 Tongue Deep invasive
37 Male 58 3
Primary: Buccal mucosa, SCC
Exophytic Secondary: Buccal mucosa, SCC
Tertiary: Tongue, VH
38 Male 61 1 Buccal mucosa Ulcerative
39 Male 61 1 Buccal mucosa Ulcerative
40 Male 75 1 Retromolar trigone Deep invasive
41 Male 45 1 Mouth ﬂoor Ulcerative
42 Male 41 4
Primary: Buccal mucosa, SCC
Deep invasive Secondary: Buccal mucosa, SCC
Tertiary: Palate, Leukoplakia
Quaternary: Lip, SCC
43 Male 45 1 Tongue Exophytic
44 Male 43 1 Tongue Exophytic
45 Male 46 3
Primary: Tongue, SCC
Exophytic Secondary: Tongue, SCC
Tertiary: Buccal mucosa, VH
46 Female 70 3
Primary: Lip, SCC
Deep invasive Secondary: Lip, SCC
Tertiary: Buccal mucosa, Leukoplakia
47 Male 47 3
Primary: Mouth ﬂoor, SCC
Exophytic Secondary: Mouth ﬂoor, SCC
Tertiary: Lip, VH
48 Male 48 1 Buccal mucosa Ulcerative
49 Male 62 3
Primary: Buccal mucosa, SCC
Deep invasive Secondary: Buccal mucosa, SCC
Tertiary: Tongue, SCC
50 Male 44 3
Primary: Buccal mucosa, SCC
Ulcerative Secondary: Tongue, Leukoplakia
Tertiary: Mouth ﬂoor, Leukoplakia
51 Male 43 1 Buccal mucosa Deep invasive
52 Male 51 1 Buccal mucosa Ulcerative
53 Male 51 1 Buccal mucosa Exophytic
54 Male 51 1 Buccal mucosa Exophytic
55 Male 42 1 Buccal mucosa Exophytic
56 Male 54 1 Buccal mucosa Deep invasive
57 Female 26 4
Primary: Buccal mucosa, SCC
Ulcerative Secondary: Buccal mucosa SCC
Tertiary: Mouth ﬂoor, Leukoplakia
Quaternary: Tongue, SCC
(a) The sequential case numbers were given in the order of the date of admission to hospital.
(b) Twenty oral cancer patients were found to manifest multiple tumor lesions when performing follow-ups 48 months after surgical procedures.
(c) For patients with multiple lesions, the sites and the pathologic diagnosis of all lesions were noted. In the current study, only the primary cancer tissues were
subjected to EBV-chip hybridizations. SCC: squamous cell carcinoma; VH: verrucous hyperplasia; SH: squamous hyperplasia.Journal of Biomedicine and Biotechnology 5
Table 2: Summary of the clinical characteristics of the studied patients.
Overall: 57 patients EBV-negative: 10 patients EBV-positive: 47 patients
Gender Gender Gender
Famale: 2 Famale: 0 Famale: 2
Male: 55 Male: 10 Male: 45
Ave. age Ave. age Ave. age
49.4 years old 53.1 years old 48.6 years old
Multiplicity Multiplicity Multiplicity
Single primary tumor: 37 Single primary tumor: 7 Single primary tumor: 30
Multiple primary tumor: 20 Multiple primary tumor: 3 Multiple primary tumor: 17
Site of the primary cancer Site of the primary cancer Site of the primary cancer
Buccal mucosa: 29 Buccal mucosa: 7 Buccal mucosa: 22
Gingiva: 9 Gingiva: 1 Gingiva: 8
Lip: 1 Lip: 0 Lip: 1
Mouth ﬂoor: 2 Mouth ﬂoor: 1 Mouth ﬂoor: 1
Palate: 4 Palate: 0 Palate: 4
Retromolar trigone: 2 Retromolar trigone: 1 Retromolar trigone: 1
Tongue: 10 Tongue: 0 Tongue: 10
Type Type Type
Deep invasive lesion: 9 Deep invasive lesion: 2 Deep invasive lesion: 7
Exophytic lesion: 26 Exophytic lesion: 2 Exophytic lesion: 24
Ulcerative lesion: 22 Ulcerative lesion: 6 Ulcerative lesion: 16
Table 3: Arbitrary viral gene expression levels in EBV-negative oral cancer specimens.
Spot on Chip(a) Case Number(b) and Gene Expression Level(c)
Mean(d) Mean + 2SD(e)
6 1 52 02 73 13 8 4 0 4 15 05 4
1 1429 1794 1034 999 4215 1428 7001 1610 1956 2418 2388 6122
2 124 646 835 449 1966 539 3649 235 11 504 896 3116
3 5 660 988 0 701 1 148 0 0 139 264 1008
4 139 204 222 0 392 0 48 0 0 6 101 371
5 25 518 1490 0 1016 0 182 0 17 747 400 1457
6 36 8997 6073 7026 1456 3038 11046 1531 3268 2999 4547 11722
R 3778 1766 2435 3905 3459 6762 11277 2487 3788 4620 4428 9976
27 153 256 1109 1 1503 138 135 0 0 254 355 1392
28 0 6621 1534 1683 6549 2578 10069 84 27 49 2919 10060
29 0 75 42 0 206 0 76 0 0 0 40 173
3 0 4360 6 4 08 8000 1 7 8 0
31 439 110 136 0 102 0 113 0 0 0 90 361
32 0 0 55 0 695 0 2 0 0 0 75 512
33 98 4 7 0 502 0 0 0 0 1164 178 938
34 23 390 937 0 4344 0 56 0 0 603 635 3321
35 224 1036 1158 1464 1793 814 2524 342 0 1006 1036 2564
36 525 2286 1127 93 1208 0 1 150 164 23 558 2075
37 0 139 9 2 286 0 0 0 11 0 45 235
38 0 76 27 0 364 0 0 0 4 0 47 275
39 0 147 76 0 2410 45 0 0 42 0 272 1777
40 0 0 61 0 284 0 8 0 0 0 35 214
41 0 0 12 0 684 0 0 4 0 12 71 502
42 0 17 0 0 357 0 4 0 0 0 38 262
43 25 18 0 0 847 0 73 0 0 0 96 626
44 177 1233 566 12 802 0 0 509 421 0 372 1207
45 0 118 322 0 571 43 0 18 74 0 115 4926 Journal of Biomedicine and Biotechnology
Table 3: Continued.
Spot on Chip(a) Case Number(b) and Gene Expression Level(c)
Mean(d) Mean + 2SD(e)
6 1 52 0 2 73 13 84 04 15 05 4
46 0 221 0 0 181 0 0 4 75 4 49 217
47 0 54 71 0 345 0 0 0 12 0 48 263
48 0 46 0 0 689 0 8 4 18 0 77 508
4 9 06 9 1 0 9 2 3 030401 0 3 6 8 2
5 0 2 1 4 1 4 5 8 7 5 1 0100 1 09 3 5 6 4
5 1 1 5 5 1 6 0 0 1 1 4 0002 9 33 4 1 2 0
52 421 5377 1626 3518 3597 643 1388 2389 4402 1548 2491 5812
53 1 1001 119 0 1046 0 0 12 140 0 232 1073
54 0 14 346 0 755 0 0 0 27 0 114 613
55 0 3801 465 49 4006 0 4 0 251 0 858 4084
5 6 0 6 0 5 7 6 6 5 4 000007 8 4 8 6
57 0 28 336 0 1213 000001 5 8 9 2 8
58 0 1 285 0 1593 0000 1 4 4 2 0 2 1198
59 17 0 184 0 2132 87 28 0 0 38 249 1577
60 10 166 0 0 536 0 13 0 121 0 85 423
61 1 1217 152 0 350 0 0 17 200 6 194 951
62 0 501 68 2 784 0 0 0 306 324 199 746
63 0 162 0 0 590 0 0 0 59 0 81 454
64 2 21 152 0 1234 0004 2 1 1 4 3 9 1 5
65 6 0 74 2 1442 0 12 0 5 0 154 1060
66 2 39 4 0 5235 0400 6 4 5 3 5 3838
67 17 9450 8745 2722 18077 7441 11458 5385 241 7549 7109 18009
68 582 209 407 0 488 0 0 0 633 0 232 769
69 116 726 22 82 1261 0 0 0 523 85 282 1132
70 15 177 0 281 85 0 0 0 57 2 62 254
71 1 62 21 0 65 0 0 0 261 0 41 204
72 0 273 0 0 306 0 0 0 42 0 62 304
73 80 23 14 0 1017 75 00001 2 1 7 5 4
7 4 1 6 00 0 8 5 0000 4 11 4 7 1
75 1650 6 1059 26 455 1113 1475 69 0 3792 965 3326
76 −186 −178 267 0 1227 0 0 0 47 1 118 936
77 279 294 7 0 26 22 0 0 446 0 107 440
78 14 443 0 0 72 0 38 17 691 0 128 607
79 2 84 3 0 612 0 0 21 457 0 118 566
80 345 1752 904 2625 1894 5532 2065 1122 10422 3957 3062 9067
81 3810 239 153 0 802 0 0 0 118 0 512 2881
82 1423 333 855 0 657 0 0 0 716 0 398 1393
83 1237 324 410 0 400 0 0 0 262 0 263 1035
84 229 67 98 443 584 0 121 236 144 0 192 573
85 38 13 0 1 778 0 3 0 448 0 128 663
86 4422 2490 945 413 931 0 12 734 1141 4 1109 3876
87 1258 246 106 26 798 0 80 7 118 0 264 1111Journal of Biomedicine and Biotechnology 7
Table 3: Continued.
Spot on Chip(a) Case Number(b) and Gene Expression Level(c)
Mean(d) Mean + 2SD(e)
61 5 2 02 73 13 8 4 0 4 1 5 05 4
88 701 99 247 152 122 0 7 0 343 0 167 609
89 1710 108 94 89 1045 0 0 138 341 0 353 1495
90r 1649 1917 1637 25454 5125 12036 16692 16458 31646 7670 12028 33016
(a) The 172-kbp EBV genome was PCR-ampliﬁed to produce 71 consecutive DNA fragments that were subsequently fabricated onto EBV-chip. These viral
DNA fragments were given Arabic numbers, except for the internal W-repeated region (as R), as indicated at the left and their residing genes were cited in
Figure 1.
(b) Ten oral cancer specimens shown here are determined to be EBV-negative by the criteria described in the Materials and Methods Section, and the numbers
correspond to the patient number shown in Table 1.
(c) The gene expression levels were represented as the arbitrary numbers of hybridization signals (blue-spots on EBV-chips) digitalized by ScanAlyze program
[32]. Owing to the highly sensitive tyramide-biotin signal ampliﬁcation method, some spots on the EBV-chips hybridized to the cDNA samples from the
EBV-negative tissues still revealed viral gene expression signals, which were considered as the background signals.
(d) Mean values with their standard deviations (SDs) of the background gene expression levels for all spots were calculated.
(e) The values of means plus two-time SD were obtained as the threshold expression levels for calculating the viral gene expression levels in EBV-positivet i s s u e
samples (Figure 2).
the viral and control gene spots is shown in Figure 1(a).
Hybridization was performed with total RNA that had been
isolated from tissue biopsies and pretreated with RQ RNase-
free DNase (Promega, Madison, WI, USA), followed by the
conversion of RNA to biotin-labeled cDNA in a reaction
mixture containing 0.5μg of total RNA, in vitro transcribed
mRNA of bacteriophage lambda DNA (1.1 and 1.2kbp PstI-
digested DNA with the amounts of 0.2ng and 0.4ng, resp.)
and two plant genes (rbcL,1ng and rca,5ng), 3μgr a n d o m
hexamers, 3μg oligo-dT primers, 200 units of MMLV reverse
transcriptase (Promega, Madison, WI, USA), dNTPs, and
biotin-16-dUTP (Roche, Mannheim, Germany). The biotin-
labeled cDNA samples (or targets) and 1ng of biotin-labeled
plant GA4 gene DNA were hybridized together to the EBV
genomic DNA spots (probes) on the chips, followed by three
washing steps. Since total RNAs instead of mRNA samples
were used, Tyramide Signal Ampliﬁcation (TSA) Biotin
System (PerkinElmer, Boston, MA, USA) was employed
to amplify the hybridization signals of the rare mRNA
species transcribed from viral genes in cancer cells. Finally,
colorimetricdetectionwasperformedaccordingtoamethod
described previously [29] by using a mixture containing
streptavidin conjugated β-galactosidase (Roche) and X-gal
substrate (Sigma-Aldrich) to produce blue hybridization
signals. The EBV-chips were then scanned with a high-
resolution scanner (UMAX PowerLook 3000, Taipei, Taiwan,
ROC). The intensities of the dose were quantiﬁed digitally
with the ScanAlyze program [32].
To conﬁrm the gene expression patterns, quantitative
real-time RT-PCRs on the CD45, β-actin, EBNA1, and
EBNA2 gene transcripts were performed. CD45 is a general
surface marker for white blood cells (WBCs) including B-
cell, and EBNA1 and EBNA2 are viral genes. For this,
0.8μg of RQ DNase-pretreated total RNAs derived from
the tumor samples, which had already tested negative in
ampliﬁcation of β-actin DNA by a regular PCR procedure,
were ﬁrst converted to cDNA using the protocol described
in the microarray experiments, except that biotin-dUTP
was replaced by regular dTTP. The cDNA samples were
further divided equally into four parts and they were
added individually to the tubes containing the PCR reagent
mixture (EZtime Real-TimePCR Premix, Yeastern Biotech
Co.,Taipei,Taiwan,ROC)andtheprimersandprobesforthe
particular genes. Subsequently, the real-time PCR ampliﬁca-
tions were performed by a sequence-detection system (ABI
7500FastReal-TimePCRSystem,AppliedBiosystems,Foster
City, CA, USA) with conditions speciﬁed earlier [33]. The
primers and probes for the CD45 and β-actin genes, with the
reporter dye FAM (6-carboxy-ﬂuorescein) and the quencher
TAMRA(6-carboxy-tetramethyl-rhodamine)attachedtothe
respective5
 -an d3
 -ends of the probes, weresynthesized (by
MDBio,Inc.,Taipei,Taiwan,ROC)accordingtotheprevious
report [29], whereas the other primer sets and probes were
synthesized in the same fashion according to the sequences
reported earlier for EBNA1 [34]a n dE B N A 2[ 35]. Since the
level of β-actin expression was used as an internal standard,
the relative mRNA levels of the target genes in each tumor
tissue/cell line were normalized to its own β-actin mRNA
content before comparing among diﬀerent testing samples.
In practice, the quantitative values obtained in the real-time
ampliﬁcation are the thresholds PCR cycle numbers (Ct),
wherethemRNAlevelofatargetgeneisreverseproportional
to its Ct, and they were presented as 2−ΔCt,w h e r e−ΔCt =
Cttarget gene − Ctβ-actin.
2.3. Statistical Evaluation on Gene Expression and Analysis.
EBV-chip hybridization experiments were also designed to
identify any viral gene that may be associated with molecular
tumorigenesis of oral cancer. The important criterion for
such EBV genes to be considered was that the expression
of the genes must be either frequently or seldom detected
among cancer samples. For this, a measuring formula was
set up speciﬁcally as follows. Brieﬂy, the threshold expression
level (the basal line distinguishing gene expression or not)
for every spot on EBV-chip was ﬁrst calculated by averaging
all digital background signals for the same spots on the
chips, which had been hybridized to those tumor specimens
determined to be EBV-negative, plus twofolds of their stan-
dard deviations or SD (Table 3). In this case, there were 718 Journal of Biomedicine and Biotechnology
numbers for the threshold expression levels corresponding
to the same numbers of EBV genomic probes (spots) on
EBV-chip. For the EBV-positive samples, actual expression
level for each spot on a chip was obtained by subtracting the
threshold expression level from the detected arbitrary digital
numberofthatspot.Therefore,thegenesthatareregardedas
expressedshouldhavetheactualexpressionlevelslargerthan
zero. The comparative expression levels were then presented
as logarithmic values of the actual expression levels that were
larger than zero, and again larger numbers indicated greater
expression levels.
Fisher’s two-tailed Exact Test was employed to analyze
the frequencies of the expression of particular viral genes
among the studied cancer specimens to associate with
the manifestation of the particular clinical characteristics;
diﬀerences of P<. 05 were considered signiﬁcant.
3. Results
3.1. EBV Infection Rate. Oral cancer patients who partic-
ipated voluntarily in the current study consisted of 55
males and 2 females with an age ranging from 26 to
79 (Table 1). They were diagnosed with malignant SCC
manifesting exophytic, ulcerative, or deep invasive lesions;
20 of them were found to have multiple tumor lesions
at the time of ﬁrst clinical examination or at the follow-
up postsurgical excisions of the primary cancer tissues.
Only the tissue removed from the primary cancer site of
each patient was included in the subsequent experiments.
Since EBV-chip hybridization detects multiple viral gene
transcripts and has been demonstrated to be accurate in
detecting EBV infection [29], the cancer specimens were
subjected directly to EBV-chip hybridization without prior
PCR determination. As the controls, total RNA from EBV-
free U937 monocytic cell line and B95-8 and P3HR1 B
cell lines were extracted and converted to biotin-cDNA,
followed by EBV-chip hybridization in parallel (Figure 1(b)).
The results of the control experiments were as expected
and consistent with those reported previously [29], thus
conﬁrming the reliability of the method. In the present
study, 57 tissue specimens were subjected to EBV-chip
hybridization to determine which cancer samples had been
infected with the virus. Microarray hybridization was always
performed up to three times until the control DNA probes
exhibited consistent and reproducible hybridization signals,
and the best EBV-chip hybridization result from each
cancer sample was selected for further analysis. According
to the criteria set previously [29], those cancer cDNAs
that hybridized and yielded low or no signals at most
spots, including that containing the EBNA1 gene, on EBV-
chips were considered as EBV-negative, whereas the EBV-
positive cancer tissues always produced patterns consisting
of multiple spots with dark hybridization signals. After
EBV-chip hybridization, a total of 10 cancer tissues was
determined to be negative in EBV infection because their
cDNA did not hybridize to viral gene spots (Figure 1(c)).
Notably, many spots on the chips hybridized with RNA
from EBV-negative tumor tissues showed low arbitrary
numbers after digitalization (Table 3), which were due to
tyramide-biotin-mediated signal ampliﬁcation and sensitive
colorimetric scanning/digitalization; these numbers were
regarded as background signals. On the other hand, tumors
from 47 patients who had OSCC were found EBV-positive;
two representative EBV-chip images derived from the EBV-
positivebiopsiesareshowninFigure 1(d).Inconclusion,this
study found a relatively high EBV prevalent rate (47/57 or
82.5%) in the patient group, higher than the results reported
by other investigations conducted in recent years, which
mainly performed PCR-based detection [15–26].
3.2. Expression of EBV Genes in Cancer Samples. To analyze
the patterns of viral gene expression in the EBV-positive
cancer samples, this study ﬁrst used the background signals
of 10 EBV-negative cancer tissues to determine the threshold
expression levels for every viral gene spots (71) on EBV-
chip (Table 3). For the given viral genes on EBV-chip that
were considered to be expressed, their arbitrary digital
signals, which were derived from hybridization with the
particular EBV-positive cancer cDNA, must be greater than
the threshold expression levels for the same spots. Thus,
the actual expression levels for the viral genes in the EBV-
positive cancer tissues were obtained by subtracting their
arbitrary numbers from the threshold expression levels
for the respective genes determined in Table 3. Since they
were large numbers, the present study used the logarith-
mic system with the larger log numbers representing the
greaterexpressionlevels(Figure 2).Owingtohighlysensitive
signal ampliﬁcation and colorimetric scanning/digitalization
methods,mostexpressedviralgeneshadtheexpressionlevels
larger than log3, and approximately half of them reached
log4 levels.
As a result of this calculation, the frequency of viral
gene expression could be indicated by the number of
cancerspecimensamongthe47EBV-positiveOSCCshowing
positive expression levels. Although the expression of the
EBNA1 gene has been used as the indicator of EBV
infection, in the present study, the EBNA1 transcript was
not detected in all of the 47 specimens, probably due to
the scarcity of the mRNA. Instead, we detected seven spots
(the spotted DNA may contain one or more genes/open
reading frames or ORFs as indicated in Figure 1(a)) whose
residing genes/ORFs expressed mRNA in 85% (>40 samples)
ofcancerbiopsies(Figure 2),andthesespotswerenumbers1
(terminal proteins, LMP2A, and 2B), 6 (W-repeated region),
35 (large tegument protein), 44 (BMRF2), 52 (EBNA3B and
3C), 75 (gp85), and the spot R or the W-repeated region
(BWRF1). Ten additional spots expressed mRNA in 75%
(>35 samples) of the specimens, which encoded envelope
proteins, enzymes, and potential regulatory proteins such as
membrane antigen p140, glycoprotein M, gp150, primase-
associated factor, vIL-10, and others. Thus, it seemed that
EBV in three quarters of cancer tissues examined in the
present study expressed proteins mainly for maintaining the
levels of the virus structural proteins and latency. On the
other hand, only three spots were expressed in less than
10% (<5 biopsies) of cancer tissues shown in Figure 2,a n dJournal of Biomedicine and Biotechnology 9
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Figure 1: Production of EBV-chip for hybridizing with cDNA samples derived from OSCC biopsies. (a) 16 control and 71 EBV DNA
fragments were organized into an 8-row by 12-column format with the size of 4.2 × 2.4mm, as speciﬁed in the previous report [29]. The
controls are located at the upper left corner included in the square box, where it contains 12 DNA fragments for 1.2 and 1.1kbp Pst I-
digested-lambda bacteriophage DNA, plant APS1, ASA1, GA4, HAT4, HAT22, LhcI, RbcL, and Rca genes, and human GAPDH and β-actin
genes. In addition, there were four dye spots that served as the negative controls. Outside the control region, 71 EBV DNA spots, with the
gene names, covering the entire EBV genome were arranged in a sequential order on EBV-chip, except that spot R was interrupted between
Spots 6 and 27. Spots R and 90r contained EBV W- (internal) and terminal-repeated, respectively, sequences. The arrangement of viral
DNA on EBV-chip could facilitate identiﬁcation of expressed genes shown in hybridization images. (b) Total RNA samples were isolated
from U937 cell line, EBV-producing B95-8 cell line, and P3HR1 cell line treated without (−) or with TPA and SB to induce the EBV lytic
cycle (+), followed by EBV-chip hybridizations. One of each of the representative reproducible images of these hybridization experiments is
shown in here, with the control regions boxed. Since U937 cells were EBV-free, no speciﬁc signal on EBV-chip spot was detected (the light
color in 90r was the nonspeciﬁc hybridization signal, as discussed in the Results section). The RNA samples derived from B95-8 and P3HR1
(+) cells contained EBV transcripts, and therefore lots of, if not all, spots showed dark color, whereas a limited number of spots yielded
signals when using EBV-latent P3HR1 (−) cDNA in hybridizations. (c) Cases numbers 41 and 54 were among those 10 EBV-negative OSCC
tissues, and basically EBV-chip hybridizations of their cDNA samples revealed no expression signal. (d) Two EBV-positive tissues, numbers
9 and 28, contained substantial numbers of EBV transcripts that resulted in many dark spots in EBV-chips. The intensities of the spots were
subsequently quantiﬁed and subjected to comparative analysis, as shown in Figure 2.10 Journal of Biomedicine and Biotechnology
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Figure 2: Hierarchical presentation of EBV gene expression patterns in forty-seven OSCC specimens. The EBV gene expression patterns in
the OSCC tissues were presented by colored codes, as pink, red, blue, green, and yellow squares represented log numbers in the respective
ranges of 5.9 - 5.0, 4.9 - 4.0, 3.9 - 3.0, 2.9 - 2.0, 1.9 - 1.0, and < 0, with larger numbers denoting greater expression levels. Among the 47 tissue
specimens, the total numbers of samples that expressed the particular viral genes were counted and listed on the left (No. exp. in tissues).
among them numbers 39 (tegument protein) and 81 (DNA
polymerase) were relevant to this study; we did not count
spot 28 (expressed in 4 biopsies) because it and spots 67 and
90r were found to contain viral sequences similar to some
human gene sequences that caused cross-hybridization [29].
The result of a low expression rate for lytic genes (BOLF1,
BILF1, and BALF5) in spots 39 and 81 suggested that EBV is
not likely to produce large quantity of virons.
To verify the data from microarray experiments, quanti-
tativereal-timePCRwasundertakentodetectthepresenceofJournal of Biomedicine and Biotechnology 11
Table 4: Statistical association of viral gene expression patterns with cancer manifestations.
Analysis of Multiplicity
Gene Spot 57: P = .0702
Lesion Single Multiple Total
Number Not Expressed 21 (44.68%) 16 (34.04%) 37 (78.72%)
Number Expressed 9 (19.15%) 1 (2.13%) 10 (21.28%)
Total 30 (63.83%) 17 (36.17%) 47 (100%)
Gene Spot 60: P = .0737
Lesion Single Multiple Total
Number Not Expressed 24 (51.06%) 17 (36.17%) 41 (87.23%)
Number Expressed 6 (12.77%) 0 (0.00%) 6 (12.77%)
Total 30 (63.83%) 17 (36.17%) 47 (100%)
Analysis of Cancer Types
Gene Spot 61: P = .0265
Cancer types Deep invasive Exophytic Ulcerative Total
Number Not Expressed 4 (8.51%) 6 (12.77%) 1 (2.13%) 11 (23.40%)
Number Expressed 3 (6.38%) 18 (38.30%) 15 (31.91%) 36 (76.60%)
Total 7 (14.89%) 24 (51.06%) 16 (34.04%) 47 (100%)
Gene Spot 68: P = .0141
Cancer types Deep invasive Exophytic Ulcerative Total
Number Not Expressed 7 (14.89%) 15 (31.91%) 6 (12.77%) 28 (59.57%)
Number Expressed 0 (0.00%) 9 (19.15%) 10 (21.28%) 19 (40.43%)
Total 7 (14.89%) 24 (51.06%) 16 (34.04%) 47 (100%)
The clinical manifestations of oral cancer (Table 1) were correlated with the chip-hybridization results of EBV-positive samples (Figure 2). The statistical
analysis method used in the present study is Fisher’s Exact Test and two-tailed.
viral EBNA1 (BKRF1) and EBNA2 (BYRF1) gene transcripts
(Figure 3). In this study, we detect that the mRNA levels
for CD45, a pan-WBC surface protein, in all cancer samples
are low, suggesting that there is no inﬁltrated blood cells
carrying EBV, which might expressed mRNA in tumors that
could cause false positive detection of EBV in microarray
analysis. Furthermore, neither the expression of the EBNA1
and EBNA2 gene was detected in either cancer tissue
determined to be EBV-negative (Case numbers 38 and
41, Table 3), whereas among the EBV-positive specimens,
numbers 2 and 47 only expressed EBNA2 but not EBNA1
mRNA , but numbers 13, 14, and 21 samples yielded strong
expression signals for both the vial genes. The results of
the quantitative real-time RT-PCR analysis (Figure 3)a r e
therefore consistent with those derived from the microarray
experiments (Figure 2).
3.3. Association of Gene Expression with Clinical Character-
istics. Upon admission to hospital, patients with oral can-
cers were subjected to careful examinations before surgical
procedures and then followed up for four years (Table 1).
We recorded multiplicity, site, type, color, and touching
sensation of every OSCC (the summary of the former three
items are shown in Table 2), and the clinical characteristics
of the samples and their viral gene expression patterns were
under statistical analysis with the Fisher’s Exact Test. The
present study did not ﬁnd any association between the
clinical manifestation in multiplicity, site, color, or touching
sensation of cancer lesions and the expression of any gene
spot (data not shown). However, there were tendencies
(Table 4), but did not reach signiﬁcant levels, that spots
57 (BRRF2 and BKRF1) and 60 (BBLF4 and BBRF1) were
expressedinfewernumberofcancerspecimensisolatedfrom
patients manifesting multiple tumor lesions (P = .0702 and
.0737, resp.). Since the gene product of BKRF1 (EBNA1)
is required for maintaining latent EBV genome and BBLF4
(helicase)isneededinalargeamountduringthereactivation
of viral replication, it seems that the expression of these
proteins is not in favor of forming multiple tumor lesions
in the same oral cavities, and the spread of EBV would
have only happened in close proximity as if the virus plays
a role in tumorigenesis. However, the functions of BRRF2
and BBRF1 are not known and their roles could not be
coincidently considered in this study. Notably, we did detect
two genes whose expression patterns were associated with
the lesion types of the cancer in the studied patients. As
seen in Table 4, the distributive frequencies of expressing
spot 61, which contained BBRF1 (capsid protein), BBRF2
(hypothetical protein), and BBRF3 (glycoprotein M), and
spot 68, which contained BDLF4 (hypothetical protein) and
BDRF1 (capsid antigen) were both signiﬁcantly greater in
OSCC exhibiting exophytic and ulcerative lesions than those
tissues with deep invasion (P = .0265 and P = .0141
for spots 61 and 68, resp.). The data suggested that the
expression of viral structural proteins, the event that occurs12 Journal of Biomedicine and Biotechnology
0
100
200
300
400
500
600
700
R
e
l
a
t
i
v
e
m
R
N
A
L
e
v
e
l
(
2
−
Δ
C
t
)
×103
U937 B95-8 38 41 2 47 13 14 21
Figure 3:Quantitativereal-timeRT-PCRoftheCD45,EBNA1,and
EBNA2 transcripts in tumor samples. Due to the limited number of
available frozen tissues, seven OSCC samples numbered 38, 41, 2,
47, 13, 14, and 21 (Case numbers are as those listed in Table 1),
with the former two categorized as EBV-negative and others as
positive, are used in this quantitative real-time PCR experiment.
The portions in the frozen tissues applying to the experiments were
all at positions adjacent to the respective tissue specimens used
in the prior EBV-chip hybridizations. The results reveal that, after
normalizing with the expression levels for the β-actin gene, the
expressions of the gene for the pan-WBC surface marker CD45 in
boththecelllinesU937andB95-8areclearlydetected,whereasthey
are low in all cancer samples, suggesting that EBV gene expression,
if any, present in inﬁltrated blood cells does not contribute to the
signals detected with EBV-chip. Tumor sample numbers 38 and
41 are EBV-negative (Table 3), samples 2 and 47 only express the
great amounts of the EBNA2 gene transcript, and the rest of cases
numbered 13, 14, and 21 have the strong expression signals for both
the EBNA1 and EBNA2 genes. In conclusion, the data from the
quantitative real-time RT-PCR analysis are in agreement with those
shown in Figure 2. In here, two identical quantitative real-time
PCR have been performed and very similar results are obtained. :
CD45; :E B N A 1 ;:E B N A 2 .
during lytic viral replication, has potential eﬀect on muscle
invasion. Despite obtaining this molecular epidemiologic
result, further pathologic investigations will be needed to
clarify their aggressive roles in cancer development.
4. Discussion
In this molecular epidemiologic study, the newly developed
EBV-chip is employed to determine the EBV prevalent rate
and viral gene expression patterns in 57 OSCC biopsies from
patients in Taiwan. By EBV-chip hybridization, a high EBV
prevalent rate of 82.5% (47/57) was detected, which was
greater than that in all previous investigations on OSCC
reported worldwide in the past decade. Because microarray
technique employs no nucleic acid ampliﬁcation (PCR)
procedure, which is likely to amplify EBV genome present
inreservoirlymphocytesinﬁltratedintumorsites(bystander
B cells), and it hybridizes only to viral gene transcripts with
as u ﬃcient sensitivity, the detected prevalent rate should
be reliable, and the result of the CD45 mRNA quantitation
shown in Figure 3 supports this conclusion. For a large virus
like EBV, which is only a portion of its sequence coding
for genes with known functions, it is possible that, due to
infrequent expression or the transcript is too small, common
molecular methods employed in previous studies may not
have identiﬁed all viral genes/coding regions. Therefore, the
use of genome-chip, instead of viral cDNA-chip, has another
advantage of facilitating the discovery of cryptic viral gene
expression, which may only be expressed at the particular
timeframe and/or tissues, in the well-designed experiments.
Furthermore, EBV-chip is capable of examining all viral
mRNA species simultaneously, but not just only one or a
few gene transcripts by reverse transcription- (RT-) PCR.
However, to limit the size and eﬀective production of EBV-
chip, more than two thirds of viral DNA fragments or spots
contained more than one genes/ORFs (Figure 1(a)). This
design facilitated a fast scanning of the entire viral genome
by a large number of samples of interest to proﬁle the global
geneexpressionpatterns.Upondetectingthegeneexpression
signal, such as those in spots 61 and 68 described above,
further molecular analyses can subsequently be employed to
characterize every detected gene/ORF in detail. Therefore,
with a single relayed procedure of RNA isolation, reverse
transcription, and hybridization, the entire EBV genomic
DNA can be scanned thoroughly for gene expression levels.
In this way, all potential viral gene expression involved
in tumorigenesis can be eﬀectively detected, analyzed, and
correlated with clinical properties of the studied tumor.
The high EBV infection rate (82.5%) detected in the
studied OSCC has been subjected to conﬁrmation by the
EBER in situ hybridization procedure (data not shown), but
the EBER was not an indicative marker in the current and
previous reports [17, 20, 26, 27], as it is in NPC [4]. Notably,
a recent investigation [23], which studied OSCC patients
admitted to hospital between 1996 and 2000 in Okinawa,
Japan, also demonstrated a very high EBV infection rate
(72%) obtained by nucleotide sequence analysis, and this
result was consistent with the data (>75%) from earlier
reports studying other Japanese populations [18, 22]. Since
Okinawa as well as the main islands of Japan is in a short
distancenorthofTaiwan,thetwoethnicgroupssharesimilar
genetics, cultures, and diets, and these reports and the
current study were conducted molecular surveys in close
time periods, the coincident detection of the high EBV
prevalent rates in both studies suggested the possibility of an
epidemiologic link between the virus and oral cancer in the
populations residing in the region. Moreover, because EBV is
an infectious agent and likely to spread, the detection of high
viral prevalent rate and the multiple lesions (17/47, Tables 1
and 2) present in the studied OSCC patients are consistent
with the concept of ﬁeld cancerization of the head and neck
[36];yetmorestudiesarerequiredtoconﬁrmthehypothesis.
To analyze and compare eﬀectively the complex gene
expressionpatternsamongthestudiedOSCCspecimens,this
study formulated and calculated the expression thresholds
for all 71 EBV DNA spots from their mean expression level
in the 10 EBV-negative cancer tumors, and any spots in
the EBV-positive specimens that were regarded as expressed
had to have an expression level larger than its respectiveJournal of Biomedicine and Biotechnology 13
expression threshold. By doing so, the numbers and types
of genes/ORFs that are expressed in the particular OSCC
sample can be determined for association investigations.
In the present study, the vast majority of EBV-positive
cancer (47 cases) expressed both latent and lytic viral gene
transcripts. Viral proteins associated with the viron, such
as BMRF2 glycoprotein, terminal proteins, large tegument
protein, gp85, p140, gpM, and gp150, and latency, such as
EBNA2, EBNA3A, EBNA3B, and EBNA3C, are expressed
in three-quarters of EBV-positive cancer tissues collected in
the current investigation (Figure 2). These results were not
unexpected as EBV tends to have latent infection in B cells
butproductivereplicationinepithelialcells[3,5],andyetthe
virus also has to maintain a certain level of latency in trans-
formed epithelium. Since the expression of the viral genes
for EBNA2 and EBNA3s is seldom reported in epithelial
cancers, a double-nested RT-PCR procedure [37] (data not
shown), as well as quantitative real-time RT-PCR (Figure 3),
is used and conﬁrmed the presence of the mRNA species in
a limited number of the studied tissues that were available
at the time. However, this discrepancy needs to be further
clariﬁed by examining more OSCC tissues with the most
sensitive and feasible PCR protocols (e.g., qPCR) and primer
sets for all noted genes. Moreover, among highly expressed
viral proteins, BMRF2 glycoprotein (spot 44, expressed in
40 OSCC), an early viral protein with nucleotide sequence
homologous to human herpesvirus 8, Kaposi’s sarcoma-
associated herpesvirus, is of particular interest because it
is expressed at high levels in hairy leukoplakia and was
found to associate with the nuclear chromatin [38]. Recent
reports further demonstrated that the glycoprotein interacts
with one family of integrins that facilitated virus attachment
and subsequent infection in oral epithelial cells, but not
in B lymphocytes [39]. In other studies [20, 22], the viral
oncogenic protein LMP-1 was frequently detected in EBV-
positive OSCC. This ﬁnding was consistent with our results
that 31 out of 47 (66.0%) cancers expressed mRNA in spot
89.Withsuchhighrequirementforthestructuralandsurface
protein synthesis taken into consideration, the data indicate
thatEBVisconstantlyassemblingviralparticlesforinfection,
and yet, in the meantime, the virus has to maintain latency
by expressing many latent gene products. In contrast, the
enzymes, such as DNA polymerase (spot 81, expressed only
in three biopsies) in the general virus replication machinery
and EBNA1 (spot 57, expressed only in 10 OSCC) for
maintaining latent viral genome, were not detected in a large
number of samples, which may be due to the unnecessary
presence of these proteins in great quantities for maintain-
ing adequate genetic materials, and thus their expression
levels were too low to be detected by hybridization. The
results then suggest that viral replication and maintaining
latency are under a delicate balance in mucosal epithelium-
derived OSCC, because EBV infection is often productive in
epithelial cells [3, 9], while the virus is known to maintain
latency in many tumor malignancies that include Burkitt’s
lymphoma (Latency I), Hodgkin’s disease, undiﬀerentiated
NPC (Latency II), EBV lymphoproliferative diseases, and
immunoblastic lymphomas in immunosuppressed patients
(Latency III). Therefore, the highly expressed nature of the
noted structural viral proteins found in the studied OSCC
provides a reasonable rationale to further investigate their
roles, directly or indirectly, in the tumorigenesis of the
cancer.
Importantly, after statistical analysis of the viral gene
expression proﬁles, this study ﬁnds speciﬁcally strong asso-
ciation between the expression frequencies of genes/ORFs
residing in DNA spots 61 (BBRF1 for capsid protein, BBRF2
[40], and BBRF3 for gpM [40, 41]) and 68 (BDLF4 and
BDRF1 for capsid protein [42]) and the clinical manifesta-
tions of OSCC. There were signiﬁcantly more patients with
oral cancer exhibiting exophytic and ulcerative lesions that
containedEBVexpressingthegenesinspot61(P = .0265)or
in spot 68 (P = .0141) than those with deep muscle invasive
lesion (Table 4). Since deep muscle invasion (migration)
is considered to be of more malignant status in clinics, a
greater expression of the viron proteins, which indicates
the productive replication of EBV, suggests an unfavorable
environmentforcancerouscelltomigrate.However,whether
the viral proteins are involved in negative regulation of cell
movement remains to be investigated. Interestingly, among
the high-expression-rate spots, vIL-10 (spot 5) was the
only protein with regulatory function and expressed in 36
(77.0%) OSCC. IL-10 is previously known as the cytokine
synthesis inhibitory factor (CSIF), which is mainly secreted
by activated TH2 cells to negatively regulate, on one hand,
the synthesis of other cytokines like IFN-γ,I L - 2 ,T N F - α,a n d
GM-CSF by TH1 cells or macrophages and downregulates
class II MHC antigen expression in monocytes to suppress
antigen-speciﬁc T cell proliferation [43]. On the other hand,
it stimulates proliferation of mast cells and thymocytes
and plays a role in B-cell activation, diﬀerentiation, and
proliferation. Although vIL-10 shares high homology with
IL-10 [44], the viral factor possesses only the activity of
CSIF, macrophage deactivation, and promotion of B-cell
proliferation [43]. Therefore, it is believed that vIL-10 acts
as an anti-inﬂammatory factor in EBV-infected tissues and
inhibits the antiviral TH1 CD4 T-cell responses [45]a n d
stimulates EBV-infected B-cell growth for spreads. It is also
possible that, as suggested by the current study from which
the majority of OSCC specimens were found to express
vIL-10, the virus releases the factor for assisting cancerous
epithelial cells to escape the protective cellular immunity.
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